Group One Trading’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.9K Sell
200
-400
-67% -$4.64K ﹤0.01% 6934
2025
Q4
$5.77K Sell
600
-300
-33% -$2.87K ﹤0.01% 7116
2025
Q3
$8.46K Buy
900
+500
+125% +$4.78K ﹤0.01% 7275
2025
Q2
$4.23K Buy
400
+300
+300% +$3.79K ﹤0.01% 7146
2025
Q1
$1.5K Buy
+100
New +$1.66K ﹤0.01% 7085
2024
Q4
Sell
-100
Closed -$2.47K 7214
2024
Q3
$2.47K Buy
+100
New +$2.59K ﹤0.01% 6094
2021
Q2
Sell
-200
Closed -$8K 8102
2021
Q1
$8K Buy
+200
New +$7.59K ﹤0.01% 7103
2020
Q2
Sell
-5,700
Closed -$165K 5752
2020
Q1
$165K Sell
5,700
-5,400
-49% -$218K ﹤0.01% 2903
2019
Q4
$576K Sell
11,100
-16,200
-59% -$941K ﹤0.01% 2321
2019
Q3
$1.5M Buy
+27,300
New +$1.4M 0.01% 1420
2019
Q2
Sell
-30,500
Closed -$922K 4906
2019
Q1
$922K Buy
30,500
+26,500
+663% +$908K 0.01% 1464
2018
Q4
$134K Buy
+4,000
New +$144K ﹤0.01% 2979
2017
Q4
Sell
-2,000
Closed -$116K 4805
2017
Q3
$116K Buy
2,000
+800
+67% +$41.8K ﹤0.01% 3137
2017
Q2
$59K Buy
+1,200
New +$55.3K ﹤0.01% 3417
2013
Q3
Sell
-4,200
Closed -$71K 5163
2013
Q2
$71K Buy
+4,200
New +$60.6K ﹤0.01% 3119

Other funds holding ANIK

Group One Trading's ANIK Position: Q1 2020 in Review

Group One Trading sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 5,196 shares — an estimated $210K sold.

Group One Trading first reported a position in ANIK in Q4 2013 and held it in 17 quarters. The position peaked at $503K in Q2 2015. 164 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Group One Trading reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Group One Trading sold 5,196 Anika Therapeutics shares in Q1 2020, an estimated $210K.
  • Group One Trading first reported a position in Anika Therapeutics in Q4 2013 and held it in 17 quarters.
  • Group One Trading's Anika Therapeutics position peaked at $503K in Q2 2015.
  • 164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Group One Trading's 13F filing for Q1 2020, filed 13 May 2020.